Fig. 1

ESR1 mutation types and distribution across different recurrence sites after CDK4/6 inhibitor therapy. The figure highlights mutation types, their frequencies, the affected protein domains, and corresponding gene exons in patients with HR + /HER2- metastatic breast cancer, based on ESR1 testing conducted on FFPE tissue samples collected in the recurrence site. Mutation types are color-coded for clarity, as indicated in the accompanying legend